| 书目名称 | Renal Cell Carcinoma | | 副标题 | Molecular Biology, I | | 编辑 | Ronald M. Bukowski (Director),Andrew C. Novick (Ch | | 视频video | | | 概述 | Includes supplementary material: | | 丛书名称 | Current Clinical Oncology | | 图书封面 |  | | 描述 | Renal cell carcinoma represents a heterogeneous group of tumors, the most common of which is clear cell adenocarcinoma. The annual incidence of this tumor appears to be rising and approximately 12,000 individuals die from this cancer annually in the United States. One third of patients who present have metastatic disease at the time of diagnosis, and another 40% who undergo nephrectomy will ultimately develop this complication. Over the past 10 years, a significant amount of new information concerning the epidemiology, mole- lar and immunologic characteristics, and therapy for patients with these tumors has appeared. The recognition that inherited forms of renal cancer exist, and that chromosomal abn- malities can be identified in these tumors, suggested a genetic basis for renal cell carcinoma. The familial cancer syndrome, Von Hippel Lindau disease, provided the setting in which the genetic abnormalites associated with the development of renal cancer were first described. Abnormalities of the VHL gene have also been detected in sporadic clear cell carcinoma, and it has now been recognized that approximately 80 % of these tumors will demonstrate ch- acteristic alterations. Current | | 出版日期 | Book 20001st edition | | 关键词 | Staging; adjuvant therapy; cancer; carcinoma; cell; epidemiology; genetics; immunotherapy; interferon; metast | | 版次 | 1 | | doi | https://doi.org/10.1007/978-1-59259-229-6 | | isbn_ebook | 978-1-59259-229-6Series ISSN 2364-1134 Series E-ISSN 2364-1142 | | issn_series | 2364-1134 | | copyright | Springer Science+Business Media New York 2000 |
The information of publication is updating
|
|
发表于 2025-3-21 18:36:40
